Investor Relations November 26, 2024 New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market Read More
Investor Relations November 1, 2024 Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th Read More
Investor Relations October 28, 2024 Nexalin Technology Announces Landmark Study on Alzheimer’s Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer’s Disease Read More
Investor Relations October 22, 2024 Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA Read More
Videos October 20, 2024 No More Side Effects: Nexalin’s Non-Invasive Approach to Treating Depression & PTSD Read More
Investor Relations October 17, 2024 New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients Read More
